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Ligandability is a prerequisite for druggability and is a much easier concept to understand, model and
predict because it does not depend on the complex pharmacodynamic and pharmacokinetic
mechanisms in the human body. In this review, we consider a metric for quantifying ligandability from
experimental data. We discuss ligandability in terms of the balance between effort and reward. The
metric is evaluated for a standard set of well-studied drug targets – some traditionally considered to be
ligandable and some regarded as difficult. We suggest that this metric should be used to systematically
improve computational predictions of ligandability, which can then be applied to novel drug targets to
predict their tractability.Introduction
The druggability of a protein target is defined as the relative ease or
difficulty of developing a small molecule that can effectively
modulate protein activity in vivo [1]. The ligandability of a protein
is defined as the relative ease or difficulty of developing a small
molecule that can bind to the protein in vitro [2]. This is an
important difference, because there are many complex pharmaco-
kinetic and pharmacodynamic (PKPD) factors that influence
druggability but not ligandability [3,4]. This makes ligandability
a prerequisite for druggability and an easier concept to measure
and predict. Consequently, there are many computational meth-
ods for predicting drug–target ligandability. All of these rely on a
structural characterisation of the target [5,6]. Before making a
prediction of ligandability it is necessary to identify the particular
binding site of interest. When the target is structurally charac-
terised, the relevant binding site tends to be known. However, the
biologically relevant binding site might not be known and/or
there might be an interest in identifying additional allosteric sites
[7]. In these cases, there are several computational methods for
predicting binding sites. Structure-based predictive methods in-
clude LIGSITE [8], PocketDepth [9], Fpocket [10], Q-SiteFinder [11]
and i-Site [12]. Once the relevant region(s) of the target has beenPlease cite this article in press as: Vukovic, S., Huggins, D.J. Quantitative metrics for drug–tar
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https://doi.org/10.1016/j.drudis.2018.02.015 identified, one of the several computational approaches can be
used to predict the druggability or ligandability of the target. These
include MAPPOD [13], SiteMap [14], WaterMap [15], fpocket [16],
DLID [17], DrugFEATURE [18], DrugPred [19], FTMap [20], JEDI
[21] and others [22,23]. It is worth noting that some methods, such
as MAPPOD and SiteMap, deliberately aim to capture features of the
binding site that will bind drug-like molecules.
Several experimental metrics for ligandability have been pro-
posed. The first class of metric is based on experimental screening
hit-rates. This idea was introduced by Hajduk et al. [4,24] who
compared hit-rates from fragment screening with the existence of
high-affinity (Kd < 300 nM), non-peptide, noncovalent inhibitors
of the target. Taking this idea further, Edfeldt et al. combined
fragment hit rates with the fragment affinities and the chemical
diversity of the hits [2]. In recent times, 19F NMR has proven to be
an important technique to rapidly assess a novel drug target using
fragment hit rates [25,26]. However, there are two caveats in the
use of the fragment hit rates alone to predict target ligandability.
Firstly, it is not guaranteed that a high hit rate for fragment
binding means that it will be easy to identify a small-molecule
inhibitor with sufficient binding affinity. Many proteins have
binding hotspots [27] that bind fragments with high affinity
[24] but are challenging drug targets. A protein surface site with
a small isolated pocket would be such an example. Even with twoget ligandability, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.02.015
icense (http://creativecommons.org/licenses/by/4.0/).
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challenging to grow or link the fragments to identify high-affinity
druglike inhibitors [28]. This is particularly true for protein–pro-
tein interactions. Secondly, hit rates must be standardised and not
depend on arbitrary thresholds, assay conditions or choice of
fragment library. This makes selection of an appropriate fragment
library very important [29]. Despite these caveats, fragment screen-
ing to assess target ligandability remains a very useful technique.
The second class of metrics is based on similarity to other targets
that are known to be tractable. However, even small differences in
sequence can markedly alter ligand binding and thus this method
can be highly inaccurate. The third metric is based on analysis of
historical data for a target. There is an abundance of experimental
data cataloguing measured protein–ligand binding affinities: Pub-
Chem [30], BindingDB [31], ChEMBL [32], Binding MOAD [33],
PDBbind [34], AffinDB [35], ChemSpider [36] and others. One of
the earliest papers on this topic suggested assessing ligandability
using the idea of maximal affinity [13]. The idea is that high
affinity ligands should have been developed for a highly ligand-
able target, whereas weaker affinity ligands should have been
developed for a target with lower ligandability. This is a logical
and effective idea, but there is a caveat. Consider two protein
targets for which a similar binding affinity has been reached. If one
of the targets requires the testing of ten-times as many ligands to
achieve this binding affinity it is arguably a significantly less
ligandable target. With this in mind, we attempt to address two
important issues with current concepts of ligandability.
 The majority of studies make a binary distinction between
druggable and undruggable targets. Ligandability and drugg-
ability are relative concepts, such that separating targets into
druggable and undruggable will always be arbitrary. A
continuous metric, such as the best-known affinity [13], isPlease cite this article in press as: Vukovic, S., Huggins, D.J. Quantitative metrics for drug–tar
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FIGURE 1
Binding affinity data as pKi values plotted against molecular weight for 19,969 com
similar picture to previous studies, with a very weak correlation of 0.33 and an a
2 www.drugdiscoverytoday.commore natural and more useful to inform decision making in
drug design.
 One of the reasons that a binary distinction of ligandability has
been favoured is that quantification of target ligandability is
difficult. Visual inspection of data and personal experience of a
given target are not ideal. Experimentally quantifying target
ligandability requires careful and unbiased analysis of a large
body of data.
We discuss an alternative to the concept of maximal affinity,
proposing a continuous metric for ligandability based on experi-
mental data. We present a concept of ligandability that is based on
the binding affinity achieved for a target as well as the effort
necessary to reach this binding affinity. We consider binding
affinity data from BindingDB [31] expressed as Ki measurements.
Figure 1 shows the pKi values for 20,000 compounds, plotted
against the molecular weight. The distribution shows a similar
picture to previous studies, with a very weak correlation of 0.33
and an apparent ceiling around pKi = 15 (1 fM affinity) [37]. We set
out with the goal of devising a metric that quantifies ligandability
in terms of the balance of effort and reward. Deriving this metric
provides us with experimental ligandability metrics for well-stud-
ied targets and allows us to assess our computational predictions of
ligandability. We have recently developed a method to predict
ligandability from the desolvation penalty required to displace the
solvent molecules from the surface of proteins, allowing a ligand
to bind [38]. Similar to other computational methods, this ap-
proach requires a high-resolution 3D structure of the target to
function. In this paper, we discuss an application of the method to
a standard set of proteins that exhibit a range of ligandability [4].
This allows us to validate the algorithm by comparing with the
experimental metric and make systematic improvements in the
future.get ligandability, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.02.015
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pounds from BindingDB [38] plotted as blue circles. The distribution shows a
pparent ceiling around pKi = 15 (1 fM affinity).
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The Ki data reported are from BindingDB. We begin by considering
the maximal affinity measurements for a set of well-studied tar-
gets. Figure 2 shows pKi-max for 442 targets along with the number
of pKi measurements for that target. The results show a very weak
correlation between maximal affinity and the number of measure-
ments (R2 = 0.11), reinforcing the concept of differential ligand-
ability. However, there is a notable difference between targets such
as dihydrofolate reductase in red (maximal pKi of 13.9 and 951 Ki
measurements) and targets such as carbonic anhydrase I in blue
(maximal pKi of 11.0 and 5689 Ki measurements). It is instructive
to consider the spread of pKi values for a given target. Figure 3
shows the pKi values in numerical order for 13 targets. If one
equates the number of compounds tested with the effort
expended, these data mean that some targets require significantly
more effort to generate high affinity inhibitors than others. Taken
together, the data suggest that maximal affinity alone is not
sufficient to quantify ligandability. With this in mind, we set
out to derive an alternative experimental measure of ligandability
metric that captures the data presented in Fig. 3.
Experimental metrics for target ligandability
We consider a standard testset of 27 well-studied protein targets:
23 assigned as druggable and four as undruggable [13]. This set has
been widely used in other studies [14–20]. The list of targets can be
seen in Table 1. The metric for quantifying experimental ligand-
ability (LIGexp) was formulated on the concept of effort and
reward: a target is highly ligandable if little effort is required to
generate a high-affinity inhibitor. For the effort metric, we use thePlease cite this article in press as: Vukovic, S., Huggins, D.J. Quantitative metrics for drug–tar
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FIGURE 2
The total number of binding affinity datapoints (pKi) plotted against the maximal pK
The correlation is weak (R2 = 0.11) reinforcing the concept of differential ligandabi
small effort (red circle) whereas carbonic anhydrase I has lower maximal pKi even t
(blue circle).total number of Ki values in BindingDB (N). The effort metric is a
surrogate for the total monetary cost. We do not use IC50 or Kd
values to maintain consistency, although this would provide
significantly more data. For the reward metric, we use the number
of reported compounds in BindingDB with a pKi > 7.0. The reward
metric attempts to characterise the broad achievement of high
binding affinity. We then define LIGexp as the proportion of
compounds tested against a target with a pKi > 7.0 (Eq. (1)).
LIGexp ¼ pKi > 7
N
ð1Þ
The metric is formulated such that a higher number represents
a greater ligandability. A threshold of 7.0 maximises the variance
in LIGexp and thus provides the best possible discrimination
between targets (for further details, see supplementary material
online). With an experimental metric for ligandability in place,
we move on to test our computational predictions. It is important
to note that this metric lacks reliability if there are insufficient
data available on the target. This is the reason why we consider
only targets where BindingDB reports >100 Ki values. We dis-
carded targets with <100 datapoints, leaving 13 of the original 27
proteins in our testset. We should note that we included all the
experimental data in BindingDB for a given target, regardless of
the physical properties. Thus, the data include compounds that
might not be considered druglike. However, Fig. 1 demonstrates
that the inclusion of compounds with a molecular weight
>500 Da is unlikely to bias the pKi distributions because in-
creased molecular weight does not correlate with increased affin-
ity above 500 Da. It is also worth noting that data for any target
are inherently biased by the nature of the drug discovery goals ofget ligandability, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.02.015
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i for a set of 442 protein targets from BindingDB [38] plotted as green circles.
lity. For example, dihydrofolate reductase protease has high maximal pKi for
hough much more effort has been put into finding a molecule with high pKi
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FIGURE 3
The distribution of pKi values for 13 targets from BindingDB [38] plotted as multicoloured circles. The 13 targets are listed in the right-hand box and the
datapoints for each target are coloured as shown. The data suggest that some targets require significantly more effort to generate high affinity inhibitors than
others. In other words, maximal affinity alone is not sufficient to quantify ligandability.
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by other concepts such as selectivity or toxicology as well as
affinity. In addition, some projects are aided by previous knowl-
edge of the protein family, which can skew the distribution of
reported affinities. An issue also arises owing to the difference
between targets where just one lead series has been pursued (with
a lot of analogues) and a target that has seen multiple lead series
(with a smaller number of analogues per series). The former could
have a range of affinities whereas the latter could have a large
number of low-affinity hits. It is also highly likely that some of
the data in BindingDB come from counter-screens against anti-
targets. In particular, kinases, bromodomains, phosphodies-
terases (PDEs) and cytochrome P450 are often used in counter-
screens. However, we consider that using only well-studied tar-
gets should mitigate these problems to an acceptable degree.
Finally, we point out that Ki values are somewhat arbitrary in
nature given their dependence on assay conditions and in many
cases by substrate concentrations. An analysis using average Kd
values (n > 3) from biophysical binding assays would be more
desirable, but such data are lacking in quantity and are still
somewhat dependent on assay conditions.
Computational prediction of target ligandability
Although the concept of ligandability based on effort-and-reward
is useful to distinguish among proteins that are already within the
drug discovery pipeline, the lack of such data prevents us from
doing the same for proteins that do not have reported Ki values. For
such proteins, effective computational prediction of ligandability
would be useful. We have reported such an approach in our
previous work when we predicted the ligandability for apo struc-
tures of bromodomains and achieved reasonable agreement withPlease cite this article in press as: Vukovic, S., Huggins, D.J. Quantitative metrics for drug–tar
4 www.drugdiscoverytoday.comexperimental data on available inhibitors [38]. This method of
prediction is applied here as well. We use a computational method
that is based on making an accurate estimation of the desolvation
penalty that accompanies ligand binding. Water plays a vital part
in small-molecule binding [39] and desolvation is one of the major
determinants of binding affinity [40–42]. We calculate this deso-
lvation penalty using a statistical mechanical method, based on
molecular dynamics simulation of the protein in explicit water.
We use the desolvation penalty as the computational prediction of
ligandability (LIGcomp). This method is explained in detail in
previous work [38]. For this reason, only a summary of the protocol
is given below.
 Stage 1. Download the PDB file from the Protein Databank.
Remove all co-solvents. Prepare the structure by adding
hydrogen atoms, assigning protonation states and optimising
the H-bond network using Schrodinger’s PrepWizard.
 Stage 2. Place the protein in a periodic box of water molecules,
such that the protein is at least 10 A˚ from the edge of the box on
all sides. Neutralise the periodic box with chloride or sodium
ions.
 Stage 3. Assign CHARMM27 [43,44] atom types and charges to
the protein. Assign TIP4P-2005 [45] parameters to the water
molecules.
 Stage 4. Restrain all protein heavy atoms harmonically with a
force constant of 1.0 kcal/mol/A˚2.
 Stage 5. Equilibrate for 1.0 ns in the constant-pressure, constant-
temperature (NPT) ensemble at 300 K.
 Stage 6. Simulate for 3.6 ns in the constant-pressure, constant-
temperature (NPT) ensemble at 300 K.
 Stage 7. Cluster 1000 snapshots from the simulation to generate
a set of hydration sites with a radius of 1.2 A˚.get ligandability, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.02.015
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TABLE 1
The protein targets from Cheng's ligandability study. Data on the
maximal reported pKi were derived from the BindingDB [31]
Target Total Ki measurements Maximum pKi
Factor Xa 3928 12.0
Thrombin 3129 12.2
HIV-1 protease 3055 14.2
Acetylcholinesterase 815 11.4
PTP1B 686 9.2
Cathepsin K 580 11.5
Caspase-1 332 9.8
c-ABL kinase 248 10.7
Angiotensin-converting enzyme 230 11.4
Phosphodiesterase 4D (PDE4D) 112 8.9
Cyclin-dependent kinase 2 105 9.7
Neuraminidase 103 10.0
Phosphodiesterase 5A 101 10.7
Cyclooxygenase-2 (COX-2) 98 8.3
IMPDH-II 95 8.2
IMPDH-I 92 9.0
Enoyl reductase 63 11.0
Aldose reductase (ALR2) 50 10.1
DNA gyrase subunit B 37 8.3
EGFR tyrosine kinase 21 9.5
MAP kinase p38 12 8.7
HIV-1 reverse transcriptase (NN) 12 7.5
Cytochrome P450 51 9 8.0
Mdm2-like p53-binding protein 3 7.7
HMG-CoA reductase 1 8.9
Hdm2 0 NA
HIV integrase 0 NA
Abbreviation: NA, not applicable.
TABLE 2
The displacement scores from the desolvation calculations and
the predicted ligandability (LIGcomp) alongside the experimental
ligandability metric from Eq. (1) (LIGexp) for the 13 targets from
Cheng's dataset with at least 100 Ki measurements
Target name Displacement
score
(kcal/mol)
Predicted
ligandability
(LIGcomp)
Experimental
ligandability
(LIGexp)
HIV-1 protease 17.8 0.76 0.77
Phosphodiesterase 5A
(PDE5A) 17.7
0.77 0.75
Angiotensin-converting
enzyme 27.4
0.16 0.59
Factor Xa 23.5 0.40 0.55
Cathepsin K 21.2 0.55 0.53
Neuraminidase 25.8 0.26 0.52
Cyclin-dependent kinase 2 28.3 0.10 0.44
Caspase-1 21.1 0.55 0.44
Phosphodiesterase 4D
(PDE4D) 19.7
0.65 0.42
Acetylcholinesterase 21.5 0.53 0.37
Thrombin 22.2 0.48 0.37
c-ABL 21.7 0.51 0.33
PTP1B 26.0 0.24 0.1
Minimum 28.3 0.77 0.77
Maximum 17.7 0.10 0.10
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N Stage 8. Calculate the binding affinity of waters in each
hydration site using inhomogeneous fluid solvation theory
[46] implemented in the Solvaware package [38].
 Stage 9. Calculate the summed binding affinity for every set of
18 connected hydration sites using the combinatorial subgraph
search algorithm implemented in the Solvaware package. As
shown previously, 18 hydration sites is approximately the size
of a 500 Da inhibitor [38]. The displacement score for each
cluster is the sum of the free energies of the constituent
hydration sites.
 Stage 10. Identify the set of 18 connected hydration sites with
the smallest displacement score. Record the displacement score
and the location of the optimal binding site.
Clusters composed of weakly bound water molecules have a
higher (less negative) displacement score and are predicted to yield
highly ligandable hotspots. Comparison of the hotspots between
proteins facilitates an assessment of relative ligandability. To
ensure that the algorithm is focused on the binding site of interest,
and not other regions of the protein, we only consider hydration
sites within 20 A˚ of the known binding site (typically 400–1000Please cite this article in press as: Vukovic, S., Huggins, D.J. Quantitative metrics for drug–tarsites). To correspond to the values of the experimental metric for
the targets studied (LIGexp), the displacement scores are then
scaled to the range 0.10–0.77.
Comparison of experimental and predicted
ligandability
The ligandability metric (LIGexp) has been computed for the 442
targets with >100 Ki values. Targets such as PDE10A (0.974),
serine/threonine protein kinase PIM-1 (0.928) and angiotensin
II receptor (0.856) are assigned high ligandability whereas targets
such as b-lactamase Ampc (0.085), carbonic anhydrase III (0.009)
and thymidylate kinase (0.000) are assigned low ligandability. All
442 ligandability values are shown in Table S1 (see supplementa-
ry material online). The correlation between LIGexp values and
the maximal pKi values is 0.53. This suggests that there is a
relationship between the maximal affinity and the spread of
affinities, as might be expected. Importantly, the correlation
between the experimental ligandability (LIGexp) and the number
of inhibitors tested is 0.11. This compares with a correlation of
0.33 between the maximal affinity and the number of inhibitors
tested. Although a good ligandability metric should not showget ligandability, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.02.015
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TABLE 3
The druggability/ligandability predictions for the 13 targets from Cheng's dataset with at least 100 Ki measurements using Solvaware,
MAPPOD, WaterMap and FTMap
Target name LIGexp Solvaware (this work) MAPPOD (nM) SiteMap FTMap
HIV-1 protease 0.77 0.76 0.66 1.06 D
Phosphodiesterase 5A (PDE5A) 0.75 0.77 0.029 1.15 D
Angiotensin-converting enzyme 0.59 0.16 130 1.00 D
Factor Xa 0.55 0.4 61 1.07 D*L
Cathepsin K 0.53 0.55 150 0.77 D
Neuraminidase 0.52 0.26 2100 0.90 D
Cyclin-dependent kinase 2 0.44 0.1 0.32 1.07 D
Caspase-1 0.44 0.55 540 0.86 B*S
Phosphodiesterase 4D (PDE4D) 0.42 0.65 0.29 1.04 D
Acetylcholinesterase 0.37 0.53 0.53 1.16 D
Thrombin 0.37 0.48 5.3 1.10 D
c-ABL 0.33 0.51 0.01 1.14 D
PTP1B 0.1 0.24 640 0.62 D
MAPPOD scores predict the maximal ligand affinity in nM, with a smaller score meaning higher druggability. The SiteMap predictions are the average DScore for each target, with a higher
score indicating greater ligandability. The FTMap predictions are denoted as D (druggable using druglike compounds), D*L (druggable only by large chemotype such as macrocycle or
foldamer), and B*S (micromolar affinity by peptide, macrocycle, or charged compound).
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ligandable targets will be overrepresented in well-studied targets
as projects on less ligandable targets could be discontinued early.
We then moved on to assess the effectiveness of the computa-
tional predictions. Table 2 shows LIGexp and LIGcomp for the 13
targets in the testset. The computational predictions show the
correct trend, with a correlation of 0.42. The targets angiotensin-
converting enzyme, neuraminidase and cyclin-dependent kinase
2 are relatively poorly predicted. All three are predicted to have
low ligandability, but the experimental data suggest that they
have intermediate ligandability. It is difficult to identify exactly
why these poor predictions arise. However, in the case of angio-
tensin-converting enzyme, it seems likely that the method fails
because of the presence of a very polar but ligandable pocket. The
majority of inhibitors are charged and bind to the catalytic zinc
ion, but the method prioritises hydrophobic sites with a low
desolvation penalty. Notably, neuraminidase also contains a very
polar pocket and binds predominantly to charged inhibitors. This
should be addressed in any future releases of the software. For
comparison, we have calculated the druggability and/or ligand-
ability for these targets using MAPPOD, SiteMap and FTMap (Table
3). Predictions are hard to compare owing to different formats of
prediction. However, it is clear that all methods do well for the
highly ligandable targets HIV-1 protease and PDE5A. Conversely,
FTMap correctly predicts angiotensin-converting enzyme as
druggable when Solvaware and MAPPOD and SiteMap predict a
lower ligandability. However, FTMap predicts that all but two of
the targets are druggable (including the least ligandable target
PTP1B) and SiteMap predicts that acetylcholinesterase and c-ABL
are highly ligandable whereas the data suggest that they are
challenging. In summary, all of these prediction algorithms have
successes and failures, but we suggest that the dataset presented
here will allow systematic improvement of these and other
computational methods.Please cite this article in press as: Vukovic, S., Huggins, D.J. Quantitative metrics for drug–tar
6 www.drugdiscoverytoday.comConcluding remarks and discussion
Accurate prediction of ligandability would be a useful tool in drug
discovery to prioritise among different drug targets at an early
stage or identify additional binding pockets on an existing drug
target. Although a prediction of druggability is more desirable
than a prediction of ligandability, druggability predictions are
confounded by multiple difficulties related to PKPD issues such as
cellular location and tissue distribution. These extend way be-
yond the structural characteristics of the target and are impossi-
ble to capture with the computational approaches now available.
Conversely, ligandability depends on the structural characteris-
tics of the target and is significantly easier to measure experimen-
tally and computationally. We have presented a new metric for
drug–target ligandability which takes into account the effort that
has been expended on each target in addition to the rewards
gained. For a given target, the metric is calculated as the fraction
of inhibitors tested that are above a specified affinity cut-off. We
selected an affinity cut-off of 100 nM, which maximises the
discrimination between targets. We suggest that this metric is
more effective than previous metrics because it does not show
bias in over-scoring well-studied targets. It is also a more robust
metric with respect to data errors and experimental uncertainty
because it does not depend on individual binding affinity mea-
surements. One issue with this metric is that the number of
compounds is not necessarily a direct measure of effort. For
example, target A might have been approached carefully by
making a few select compounds whereas target B could have
been approached by screening a large library at low cost. Alter-
natively, the chemistry for inhibitors of target A might be more
challenging and require more synthetic effort per final molecule.
However, by selecting only well-studied targets with >100 Ki
values, we attempted to mitigate these problems. To further
bolster the data, we could use IC50 values or Kd values. It would
also be extremely useful to have access to internal data fromget ligandability, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.02.015
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TABLE 4 (Continued )
Target Experimental
ligandability
(LIGexp)
pKi
values
(N)
Coagulation factor X 0.554 3928
Somatostatin receptor 0.549 1915
Histamine receptor (h4) 0.537 1071
Delta opioid receptor 0.521 1752
5-Hydroxytryptamine receptor 2c
(5HT2c)
0.519 1552
Adrenergic receptor alpha 0.495 2862
Cannabinoid receptor 1 (CB1) 0.485 2498
Muscarinic acetylcholine receptor m2 0.485 1264 s
 P
O
ST
SC
R
EE
Npharmaceutical companies. This information could be shared
without risking intellectual property and could provide some
very useful post-competitive data. We calculated the ligandabil-
ity metric for 442 targets from BindingDB. We consider that the
dataset of 442 targets might be too large for validation of compu-
tational methods. However, restriction to targets with at least
1000 Ki measurements yields a dataset of 54 targets with a range
of ligandability metrics from 0.125 to 0.890. These targets are
listed in Table 4 and could be used in future work as a bench-
marking set for computational methods. Using only these large
datasets mitigates some of the issues discussed above such as
dependence on assay conditions, lack of diversity in the dataset
and experimental uncertainty in the data. Given the importancePlease cite this article in press as: Vukovic, S., Huggins, D.J. Quantitative metrics for drug–tar
TABLE 4
The experimental ligandability metric from Eq. (1) (LIGexp) for 54
targets from the BindingDB with at least 1000 Ki measurements
Target Experimental
ligandability
(LIGexp)
pKi
values
(N)
Trace amine-associated receptor 1
(taar1)
0.890 1531
Apoptosis regulator bcl-2 0.828 1600
Histamine receptor (h3) 0.824 3082
Glucocorticoid receptor 0.799 1002
Melatonin receptor 0.776 1493
HIV-1 protease 0.765 3055
Poly-ADP-ribose polymerase 1 (PARP1) 0.748 1164
Carbonic anhydrase XII 0.739 1998
Sigma opioid receptor 0.736 1567
Melanin-concentrating hormone
receptor
0.731 1541
Nociceptin receptor 0.721 1054
DRD2 0.692 1388
a-Adrenergic receptor (1a and 1d) 0.688 1568
G-protein-coupled receptor 44 0.687 1002
5-Lipoxygenase/FLAP 0.678 1476
Corticotropin-releasing factor receptor 1 0.675 1346
Serotonin (5-HT) receptor 0.674 6889
Carbonic anhydrase IX 0.666 2942
Leukocyte elastase 0.659 1133
D(3) dopamine receptor 0.650 3621
Histamine h1 receptor 0.614 1422
Kappa opioid receptor 0.604 3333
5-Hydroxytryptamine receptor 2a (5-
HT2a)
0.604 1972
mu-Type opioid receptor (mu) 0.597 2510
Carbonic anhydrase II 0.594 5949
D(4) dopamine receptor 0.584 1951
Sigma-1 receptor 0.580 1557
Serotonin transporter (sert) 0.579 2692
Cannabinoid receptor 2 (CB2) 0.577 3378
Adenosine receptor a2b 0.575 1616
Melanocortin receptor 4 0.556 2028
and m4
Carbonic anhydrase IV 0.475 1965
Dopamine d2 receptor 0.465 5652
Neuronal acetylcholine receptor 0.459 1224
Dopamine transporter (dat) 0.455 3246
Adenosine receptor a2a 0.448 4138
Orexin receptor 2 0.441 1586
Norepinephrine transporters (net) 0.403 1435
Trypsin 0.376 1988
Thrombin 0.375 3129
Dopamine d1 receptor 0.371 1198
Adenosine receptor a1 0.340 3305
Orexin receptor 1 0.321 1405
Carbonic anhydrase I 0.255 5689
Monoamine oxidase 0.195 1194
Voltage-gated potassium channel 0.125 1175
Re
vi
ewof appropriate target selection and the ability to make predictions
on one or relatively few structures, we consider the expenditure
of significant computational resource on prediction of drug–
target ligandability to be a worthwhile expenditure.
To make predictions of ligandability, we used a computational
method based on the thermodynamics of the water network at the
protein surface. The concept is that a cluster of weakly bound
water molecules represents a ligand-binding hotspot, where a
small desolvation penalty can be paid before forming the protein-
–ligand interactions. The method employed makes quantitatively
accurate predictions of solvation thermodynamics [47,48]. We
have also used this approach to consider all hydration sites on
the surface of a protein (typically 2000–4000 sites) [38]. This global
search finds the region of the protein with the lowest desolvation
energy. A global search is useful for proteins for which the binding
site is not known and allows an early assessment of traditionally
difficult targets to predict tractability [49,50]. It is important to
state that analysis of hydration sites around a protein only looks at
part of the story for small-molecule binding. The desolvation
penalty for displacing a cluster of hydration sites is compensated
by interactions that a ligand will create once inside the volume of
displaced hydration sites. For this reason, hydration sites with
strongly bound water molecules tend not to be predicted as hot-
spots. In future work, this method could be developed by incor-
porating co-solvents and fragment probes into the simulation toget ligandability, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.02.015
www.drugdiscoverytoday.com 7
REVIEWS Drug Discovery Today Volume 00, Number 00 December 2018
DRUDIS-2199; No of Pages 9
Review
s
P
O
ST
SC
R
EENexplicitly consider the balance between protein–solvent and
protein–ligand interactions. This type of approach has been taken
with FTMap [51], which instead of displaceability of solvent
molecules tests different molecular fragments against the entire
surface of the protein to detect regions for the best binding. We
have included the comparison of scores with FTMap and with
MAPPOD and WaterMap (see Table 3).
We tested the method on 13 targets from BindingDB, each with
>100 Ki measurements. The correlation between the experimental
and predicted ligandability was 0.42 and this suggests that the
computational methodcouldbeused asa flagtoidentify particularly
challenging targets. However, although these results are reasonable,
there is significant room for improvement. Importantly, the quan-
titative experimental metric described here enables systematic im-
provement of computational methods and we recommend its
adoption in assessing predictive tools. It is important to note that
there is an additional factor that should be applied to drug–target
assessment using concepts of ligandability and that is the binding
affinity of the cognate binding partner. For two drug targets with
equal ligandability, it will be easier to inhibit the target which has a
weaker affinity for its cognate binding partner. For this reason, we
suggest that drug–target assessment should be focused on inhibit-
ability rather than ligandability. This could be achieved easily with a
small number of in vitro measurements. It is likely to be many years
before computational methods can make accurate predictions of
drug–target ligandability. However, accurate predictions of drug–
target ligandability and inhibitability are achievable and will help us
to extend the druggable genome in an effective manner.
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